High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer

Center for Cancer Immune Therapy (CCIT), Department of Hematology, University Hospital Herlev, Copenhagen, 2730, Herlev, Denmark.
Breast Cancer Research and Treatment (Impact Factor: 3.94). 03/2010; 125(2):395-406. DOI: 10.1007/s10549-010-0844-9
Source: PubMed


As pre-existent immunity might be a reflection of an emerging anticancer response, the demonstration of spontaneous T-cell responses against tumor associated antigens (TAAs) in cancer patients may be beneficial before clinical development of dendritic cell (DC)-based cancer vaccines, because it will help to identify likely responders to TAAs among patients who qualify and may benefit from this form of immune therapy. This study aimed to determine pre-existent T-cell reactivity against the tumor suppressor protein p53 in breast cancer patients (BCP) at the time point of primary diagnosis. After a short-term stimulation with autologous wt p53 mRNA-transfected DCs, IFN-γ enzyme-linked immunosorbent spot (ELISPOT) analysis revealed p53-reactive T cells in the peripheral blood of more than 40% (15 of 36) of the tested patients. Both CD4(+) and CD8(+) p53-specific T cells secreted IFN-γ after stimulation with p53-transfected DCs. Interestingly, more than 72% (13 of 18) of patients with high p53 (p53(high)) expression in tumors were able to mount a p53-specific IFN-γ T-cell response, in contrast to only 10% (1 of 10) of healthy donors and 11% (2 of 18) of patients with low or absent p53 (p53(low)) expression in tumors. Furthermore, significantly higher secretion of IL-2 was detected in peripheral blood mononuclear cells after stimulation with p53-transfected DCs from patients with p53(high) tumor expression compared to patients with p53(low) tumor expression, whereas secretion of IL-10 was predominant in the latter group. The high frequency of spontaneous wt p53-reactive T cells detected in the peripheral blood of primary BCP with accumulation of p53 in tumor provides a rationale to consider DCs transfected with mRNA encoding wt p53 for clinical investigation in these patients.

Download full-text


Available from: Eva Balslev, Oct 06, 2015
35 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mutations in the TP53 gene are a feature of 50% of all reported cancer cases. In the other 50% of cases, the TP53 gene itself is not mutated but the p53 pathway is often partially inactivated. Cancer therapies that target specific mutant genes are proving to be highly active and trials assessing agents that exploit the p53 system are ongoing. Many trials are aimed at stratifying patients on the basis of TP53 status. In another approach, TP53 is delivered as a gene therapy; this is the only currently approved p53-based treatment. The p53 protein is overexpressed in many cancers and p53-based vaccines are undergoing trials. Processed cell-surface p53 is being exploited as a target for protein-drug conjugates, and small-molecule drugs that inhibit the activity of MDM2, the E3 ligase that regulates p53 levels, have been developed by several companies. The first MDM2 inhibitors are being trialed in both hematologic and solid malignancies. Finally, the first agent found to restore the active function of mutant TP53 has just entered the clinic. Here we discuss the basis of these trials and the future of p53-based therapy.
    Nature Reviews Clinical Oncology 10/2010; 8(1):25-37. DOI:10.1038/nrclinonc.2010.174 · 14.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Dendritic cells (DC) are professional antigen-presenting cells currently being used as a cellular adjuvant in cancer immunotherapy strategies. Unfortunately, DC-based vaccines have not demonstrated spectacular clinical results. DC loading with tumor antigens and DC differentiation and activation still require optimization. An alternative technique for providing antigens to DC consists of the direct fusion of dendritic cells with tumor cells. These resulting hybrid cells may express both major histocompatibility complex (MHC) class I and II molecules associated with tumor antigens and the appropriate co-stimulatory molecules required for T-cell activation. Initially tested in animal models, this approach has now been evaluated in clinical trials, although with limited success. We summarize and discuss the results from the animal studies and first clinical trials. We also present a new approach to inducing hybrid formation by expression of viral fusogenic membrane glycoproteins.
    Cytotherapy 08/2011; 13(7):774-785. DOI:10.3109/14653249.2011.553593 · 3.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PD-L1 (CD274) contributes to functional exhaustion of T cells and limits immune responses in patients with cancer. In this study, we report the identification of an HLA-A2-restricted epitope from PD-L1 and we describe natural, cytolytic T-cell reactivity against PD-L1 in the peripheral blood of cancer patients and healthy individuals. Notably, PD-L1-specific T cells were able not only to recognize and kill tumor cells, but also PD-L1-expressing dendritic cells (DC) in a PD-L1-dependent manner, insofar as PD-L1 ablation rescued DC from killing. Furthermore, by incubating non-professional antigen presenting cells (APC) with long peptides from PD-L1 we found that PDL1 was rapidly internalized, processed and cross-presented by HLA-A2 on the cell surface. Apparently, this cross presentation was TAP-independent, since it was performed not only by Bcells but in addition by TAP-deficient T2-cells. This is intriguing, since soluble PD-L1 has been detected in the sera from cancer patients. PD-L1-specific cytotoxic T cells (CTL) may boost immunity by the killing of immune suppressive tumor cells as well as regulatory cells. However, PD-L1-specific CTL may as well suppress immunity by the elimination of normal immune cells especially PD-L1 expressing mature DC.
    Cancer Research 01/2013; 73(6). DOI:10.1158/0008-5472.CAN-12-3507 · 9.33 Impact Factor
Show more